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The t(8;21) translocation is one of the most frequent cytogenetic abnormalities in acute
myeloid leukaemia (AML) and results in the RUNX1/RUNX1T1 rearrangement. Despite the
causative role of the RUNX1/RUNX1T1 fusion gene in leukaemia initiation, additional genetic
lesions are required for disease development. Here we identify recurring ZBTB7A mutations in
23% (13/56) of AML t(8;21) patients, including missense and truncating mutations resulting
in alteration or loss of the C-terminal zinc-finger domain of ZBTB7A. The transcription factor
ZBTB7A is important for haematopoietic lineage fate decisions and for regulation of
glycolysis. On a functional level, we show that ZBTB7A mutations disrupt the transcriptional
repressor potential and the anti-proliferative effect of ZBTB7A. The specific association of
ZBTB7A mutations with t(8;21) rearranged AML points towards leukaemogenic cooperativity
between mutant ZBTB7A and the RUNX1/RUNX1T1 fusion.
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B
lock of myeloid differentiation is one of the hallmarks of
acute myeloid leukaemia (AML). First insights into this
key mechanism were gained by the discovery of the
t(8;21)(q22;q22) translocation, which was the first balanced
translocation described in a tumour and results in the RUNX1/
RUNX1T1 fusion gene (also known as AML1/ETO)1,2. The
RUNX1/RUNX1T1 rearrangement is one of the most frequent
chromosomal aberrations in AML and defines an important
clinical entity with favourable prognosis according to the World
Health Organization classification3. The RUNX1/RUNX1T1
fusion protein disrupts the core-binding factor complex, and
thereby blocks myeloid differentiation. However, in vivo models
indicate the requirement of additional lesions, such as of KIT or
FLT3 mutations, for leukaemogenesis as the RUNX1/RUNX1T1
fusion gene alone is not sufficient to induce leukaemia4–8. In the
present study, we set out to identify additional mutations in AML
t(8;21) and discovered frequent mutations of ZBTB7A—encoding
a transcription factor important for the regulation of
haematopoietic development9 and tumour metabolism10. It is
very likely that ZBTB7A mutations are one of the important
missing links in RUNX1/RUNX1T1-driven leukaemogenesis.
Results
ZBTB7A is frequently mutated in AML t(8;21). To identify
additional cooperating mutations, we performed exome
sequencing of matched diagnostic and remission samples from
two AML patients with t(8;21) translocation and detected 11 and
12 somatic variants, respectively (Supplementary Table 1).
ZBTB7A was the only mutated gene identified in both patients.
ZBTB7A (also known as LRF, Pokemon and FBI-1) is a member
of the POZ/BTB and Krüppel (POK) transcription factor family9,
which is characterized by an N-terminal POZ/BTB
protein–protein interaction domain and C-terminal C2H2 zinc
fingers11. The first patient carried a homozygous missense
mutation resulting in the amino-acid change R402H
(NM_015898:exon2:c.1205G4A:p.R402H) affecting the highly
conserved zinc-finger domain, while a heterozygous frameshift
insertion (NM_015898:exon2:c.522dupC:p.A175fs) resulting in
loss of the zinc-finger domain was identified in the second
patient. Both mutations were validated by Sanger sequencing
(Supplementary Fig. 1; Supplementary Table 2). Using targeted
amplicon sequencing of ZBTB7A and 45 leukaemia relevant
genes, we screened 56 diagnostic AML t(8;21) samples, including
one of the two samples analysed by exome sequencing (UPN 1),
whereas for the other one (UPN 2) availability of material was
insufficient. ZBTB7A mutations were identified in 13 of 56
patients (23%; Fig. 1a,b; Supplementary Table 3). Patient
characteristics are summarized in Supplementary Table 4. Two
recurring mutational hotspots (A175fs and R402) in exon 2 were
identified altering or resulting in loss of the zinc-finger domain
(Fig. 1a). It was previously shown that the zinc-finger domain of
ZBTB7A is essential for DNA binding12. Structural modelling
revealed that arginine 402 binds into the major groove of the
DNA double helix and likely contributes to the affinity or
sequence specificity of the DNA interaction of the zinc-finger
domain of ZBTB7A (Fig. 2a). We confirmed that both ZBTB7A











































































Figure 1 | ZBTB7A mutations in AML t(8;21). (a) ZBTB7A protein (NP_056982.1) and identified mutations (red¼ truncating; black¼missense)
illustrated using IBS software31. Amino-acid positions are indicated below the graph. BTB, BR-C ttk and bab; NLS, nuclear localization sequence; Zf, zinc
finger. (b) Mutational landscape of 56 diagnostic AML samples with t(8;21) translocation. Each column represents one patient, each line one of the
analysed genes or cytogenetic markers.
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Variant allele frequency ranged from 5.4 to 76.2% (cut-off 2%)
and 4 of 13 patients (31%) harboured two mutations of ZBTB7A.
Fourteen of 17 mutations (82%) were validated by Sanger
sequencing (Supplementary Fig. 1). Somatic status was confirmed
in a total of three patients with available remission samples.
Thirty-two additional samples of t(8;21)-positive AML with
inadequate sample availability for gene panel sequencing were
analysed by Sanger sequencing of exon 2 (encoding amino acids
1–421) resulting in the identification of two ZBTB7A mutations
(2/32; 6%). This lower mutation frequency might be due to the
lower sensitivity of Sanger sequencing and incomplete coverage of
the coding exons of ZBTB7A (we were not able to
reliably amplify exon 3 encoding amino acids 422–584).
To evaluate the consequences of truncating ZBTB7A mutations
on the protein level, we performed western blot analysis for
one patient with available material and detected a shorter
form of the ZBTB7A protein resulting from the R377X mutation
(Supplementary Fig. 2).
Recently, frequent ASXL2 mutations were identified in t(8;21)
AML13. In our cohort, ZBTB7A and ASXL2 mutations occurred
at similar frequencies (Fig. 1b) and 5 of 13 patients carried
mutations in both genes; however, there was no significant
association of mutated ZBTB7A and mutations in ASXL2
(Fisher’s exact test, P¼ 0.12) or any other recurrently mutated
gene. Alterations of ASXL1 were mutually exclusive with
genetic lesions of ZBTB7A suggesting alternative routes of
leukaemogenesis. Similarly, mutations of ZBTB7A and KIT
were exclusive in all, but one patient. In the exome data of 22
patients with inversion inv(16) (another rearrangement
disrupting the core-binding factor complex in AML), we found
a single ZBTB7A mutation (A211V). Of note, we did not find
any ZBTB7A mutations by exome sequencing of 50 patients
with cytogenetically normal AML (CN-AML) or 14 AML patients
with chromosomal aberrations other than t(8;21) or inv(16).
These results point towards a specific association between
ZBTB7A alterations and the RUNX1/RUNX1T1 fusion.
Mutations disrupt the anti-proliferative function of ZBTB7A.
To assess the functional consequences of the identified ZBTB7A
mutations, we performed luciferase reporter gene assays. It is
known that ZBTB7A represses the expression of ARF (alternate
open reading frame of CDKN2A)14. In contrast to wild-type
ZBTB7A, the R402H, R402C, A175fs or R377X mutants failed to
repress a luciferase reporter containing ZBTB7A-binding
elements derived from the ARF promoter (Fig. 3a). Expression
of ZBTB7A constructs was confirmed by western blot (Fig. 3b).
In light of recent reports about the negative regulation of
glycolysis by ZBTB7A10, we assessed the expression of glycolytic
genes (SLC2A3, PFKP and PKM) in the RNA-sequencing data
from our AML t(8;21) patients (Supplementary Fig. 3).
In ZBTB7A-mutated patients (n¼ 5), we found a significantly
higher expression of PFKP (Student’s t-test, P¼ 0.03) compared
with patients without any detectable ZBTB7A mutation (n¼ 11).
On average, PKM and SLC2A3 also showed higher expression
levels in patients with ZBTB7A mutations, but did not reach
statistical significance (Student’s t-test, P¼ 0.17 and P¼ 0.54,
respectively). In the latter case, the difference in the mean values
can be attributed mainly to an outlier in the ZBTB7A-mutated
group with very high SLC2A3 expression. Expression levels of
ZBTB7A were similar in both the patient groups, compatible with
inactivation of ZBTB7A on the genetic level rather than on the
transcriptional level.
The C-terminal part of ZBTB7A is important for nuclear
localization15. Because some mutations result in loss of the
C-terminal zinc-finger domain and nuclear localization signal, we
evaluated the cellular localization of mutant ZBTB7A. Whereas
wild-type ZBTB7A was detected in the nucleus, immuno-
fluorescence staining of the A175fs and R377X mutants showed
an altered cytoplasmic localization (Fig. 3c). In contrast,
mutants R402H and R402C exhibited a variable cellular
localization with cytoplasmic protein detectable only in a minor
subset of cells (Supplementary Fig. 4a,b). Amino-acid substitutions
of R402 showed a smaller increase in cytoplasmic protein fraction
compared with truncation mutants as analysed by western blot
(Supplementary Fig. 4c). Ultimately, the observed effect of
mutations on ZBTB7A localization remains to be confirmed in
appropriate primary patient material, which was not available in
our study.
In the t(8;21) translocation-positive AML cell line Kasumi-1,
retroviral expression of wild-type ZBTB7A inhibited cell growth,
whereas this anti-proliferative effect was not observed upon
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Figure 2 | Impact of ZBTB7A mutations on DNA binding. (a) Model
for the C-terminal zinc-finger domain of ZBTB7A comprising residues
382–488. The model is depicted as yellow ribbon with highlighted
secondary structure. Zinc ions are shown as grey spheres. DNA is shown in
brown with a grey molecular surface. R402 (purple) binds into the major
groove and likely contributes to the affinity or sequence specificity of the
DNA interaction of the zinc-finger domain. (b) Biotinylated oligonucleotides
containing the ZBTB7A (alias: Pokemon) consensus binding motif
(POK WT) or a mutant thereof (POK mut)14 used in DNA pull-down
experiments. Spheres illustrate streptavidin-coated beads. (c) DNA
pull-down using protein lysates from HEK293T cells expressing wild-type
or mutant ZBTB7A. Western blot analysis shows that A175fs and
R402H fail to bind oligonutides with a ZBTB7A-binding site (POK WT).
Oligonucleotides with a mutated binding site (POK mut) were used as
negative control. Input lanes were loaded with 10% of the protein lysate
used for each binding reaction.
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expression of the A175fs ZBTB7A mutant (Fig. 3d). The R402C
mutant expressing Kasumi-1 cells showed a trend towards reduced
cell growth, suggesting residual activity. On the basis of this
observation, we expressed ZBTB7A wild type or its mutants
together with the RUNX1/RUNX1T1 fusion in lineage-negative
murine bone marrow cells and performed colony-forming cell
(CFC) assays. ZBTB7A expression led to a significant decrease in
the number of colonies in primary CFC (87±12.6 versus 45±5.8,
Student’s t-test, Po0.0001), while this effect was lost for both
mutants tested (Fig. 3e). These findings support an oncogenic
cooperativity between RUNX1/RUNX1T1 and ZBTB7A mutations.
Prognostic relevance of ZBTB7A expression in CN-AML. The
identification of a novel recurrently mutated gene demands the
evaluation of its clinical relevance. We did not find a significant
difference in overall or relapse-free survival between
t(8;21)-positive AML patients with wild-type or mutant ZBTB7A
(Supplementary Fig. 5). However, this evaluation was limited by
the relatively small cohort size. Considering the potential role of
ZBTB7A as tumour suppressor in AML and its anti-proliferative
properties, we correlated ZBTB7A expression with clinical
outcome in a larger cohort of AML patients (GSE37642). There
was no significant difference in ZBTB7A expression levels
between cytogenetic subgroups of AML (Supplementary Fig. 6).
Remarkably, in over 200 CN-AML patients treated on clinical
trial (NCT00266136), high expression of ZBTB7A was associated
with a favourable outcome (Fig. 3f; Supplementary Fig. 7),
suggesting a relevance in AML beyond the t(8;21) subgroup. The
favourable prognostic impact of high ZBTB7A transcript levels
was most obvious in elderly patients (age 460 years) and high
ZBTB7A expression was associated with a ‘low molecular risk
genotype’ (mutated NPM1 without FLT3-ITD; Supplementary
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Figure 3 | Functional consequences of ZBTB7A mutations and clinical relevance of ZBTB7A expression. (a) Luciferase assay in transiently transfected
HEK293T cells using the pGL2-p19ARF-Luc reporter combined with expression constructs for wild-type and mutant ZBTB7A. (b) Western blot of ZBTB7A
constructs expressed in HEK293T cells. (c) Sub-cellular localization of ZBTB7A wild type, R377X and A175fs in transiently transfected U2OS cells. Scale
bar, 25mm. (d) Growth of Kasumi-1 cells stably expressing ZBTB7A wild type or mutants. (e) CFC assay of murine bone marrow lineage-negative cells co-
expressing RUNX1/RUNX1T1 and wild-type or mutant ZBTB7A. (f) Overall survival of patients with CN-AML according to ZBTB7A expression (log-rank
test, P¼0.0004). *Two-tailed, unpaired Student’s t-test, Po0.05; NS, not significant. Bar graphs or growth curves represent mean±s.d. of three
independent experiments.
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high ZBTB7A expression with favourable outcome in an inde-
pendent CN-AML patient cohort16,17 (Supplementary Fig. 8).
Discussion
In summary, we have identified ZBTB7A as one of the most
frequently mutated genes in t(8;21)-positive AML. Consistent
with our findings, ZBTB7A mutations in 3 of 20 (15%) AML
t(8;21) patients and 1 of 395 AML inv(16) patients were
reported18 during the revision of the present manuscript. Our
functional analyses indicate that ZBTB7A mutations result in loss
of function, due to alteration or loss of the zinc-finger motives.
Beyond DNA binding, the zinc-finger domain of ZBTB7A is also
known to interact with TP53 and BCL6 (ref. 9). Thus, multiple
pathways might be influenced by alteration or loss of the ZBTB7A
zinc-finger domain. The N-terminal missense mutations in the
BTB domain may result in failure of co-repressor recruitment.
Considering that 4 of 13 of patients had more than one ZBTB7A
mutation, our finding that overexpression of wild-type ZBTB7A
leads to reduced proliferation of Kasumi-1 cells and a decreased
number of CFCs of murine bone marrow cells, we suggest that
ZBTB7A acts as a tumour suppressor in t(8;21)-positive AML.
Initial studies characterized ZBTB7A as proto-oncogene in
various tissues14,19. For example, Maeda et al. demonstrated
that transgenic mice with Zbtb7a overexpression in the immature
T- and B-lymphoid lineage develop precursor T-cell lymphoma/
leukaemia14. In contrast, it was more recently shown that
ZBTB7A can also act as a tumour suppressor. Overexpression
of Zbtb7a in murine prostate epithelium did not result in
neoplastic transformation; unexpectedly, Zbtb7a inactivation lead
to the acceleration of Pten-driven prostate tumorigenesis20.
Recently, somatic zinc-finger mutations of ZBTB7A were found
at low frequencies (o5%) in a variety of solid cancers suggesting
a common mechanism across tumour entities21. In fact, the
de-repression of glycolytic genes upon deletion or mutation of
ZBTB7A10,21 might underlie the loss of anti-proliferative
properties that we observed for ZBTB7A mutants A175fs
and R402C in the present study. Any inactivating alteration of
ZBTB7A will likely increase glycolysis, and, thus, helps the
tumour cells to produce more energy. Besides tumour
metabolism, it is known that ZBTB7A also plays an important
role in haematopoietic lineage fate decisions9. During
lymphopoiesis ZBTB7A regulates B-cell development22, whereas
in the myeloid lineage it is essential for erythroid
differentiation23. Thus, ZBTB7A mutations may contribute to
the block of differentiation in AML t(8;21).
The favourable prognostic relevance of high ZBTB7A
expression in CN-AML, which accounts for half of all AML
patients, may point towards a more general tumour suppressor
role of ZBTB7A in myeloid leukaemia. In particular, the
anti-proliferative properties of ZBTB7A may slow down disease
progression. High ZBTB7A expression as a favourable prognostic
marker has been reported also in colorectal cancer10, consistent
with a clinicobiological role of ZBTB7A across malignancies of
multiple tissue origins. Given that somatic mutations of ZBTB7A
seem to be absent or rare in CN-AML, other mechanisms,
including epigenetic changes or alterations of upstream
regulators, may lead to inactivation or downregulation of
ZBTB7A.
Our discovery of frequent ZBTB7A mutations in AML with
t(8;21) translocation, one of the most common translocations
in AML and the first balanced translocation identified in
leukaemia1, demonstrates that the mutational landscape of AML
is still not fully understood. Further studies will be required to
unravel the mechanism underlying leukaemogenic cooperativity
between mutated ZBTB7A and the RUNX1/RUNX1T1 fusion gene.
Methods
Patients. AML samples were collected within the German Cancer Consortium
(DKTK) at the partner sites Munich and Dresden. Patients were treated according
to the protocols of Acute Myeloid Leukemia Cooperative Group (AMLCG) or
Study Alliance Leukemia (SAL) multicentre clinical trials. Study protocols were
approved by the Institutional Review Boards of the participating centres. Informed
consent was received in accordance with the Declaration of Helsinki.
Sequencing. Exome sequencing (mean coverage: 87x; range 80–90x) was per-
formed on a HiSeq 2000 Instrument (Illumina), using the SureSelect Human All
Exon V5 kit (Agilent). Pretreatment blood or bone marrow specimens from 56
AML patients with t(8;21) translocation were sequenced using Haloplex custom
amplicons (Agilent) and a HiSeq 1500 instrument (Illumina). Target sequence
included the entire open-reading frame of ZBTB7A in addition to 45 leukaemia-
related genes or mutational hotspots (Supplementary Table 3). Variant calling was
performed as described previously24. Sanger sequencing of PCR-amplified genomic
DNA was carried out using a 3500xL Genetic Analyzer (Applied Biosystems).
Primer sequences are provided in Supplementary Table 2. Sequencing of messenger
RNA was performed using the TruSeq RNA Sample Preparation protocol, followed
by sequencing on a HiSeq 2000 Instrument (Illumina). RNA sequence reads were
aligned to the human genome (hg19) using STAR25 (version 2.4.1b). Reads per
gene were counted using HTseq26 (version 0.6.1) with intersection-strict mode and
normalized for the total number of reads per sample.
Structural modelling. Suitable templates for the modelling were searched with
HHPRED27, using the zinc-finger domain of ZBTB7A as input sequence. The
highest scoring homologue, for which a structure of a DNA complex is available,
was the Wilms tumour suppressor protein28 (PDB accession code 2J9P, E-value
4.8E–29, P-value 1.3E–30). The model for ZBTB7A was generated on the basis of
2J9P using MODELLER29. Importantly, 2J9P also contains an arginine at the
equivalent position of ZBTB7A’s R402, allowing us to model the function of R402
as major groove binder with confidence.
Plasmids. The pcDNA3.1-His-ZBTB7A expression construct was a gift from
Takahiro Maeda (Boston). ZBTB7A A175fs, R377X, R402C and R402H mutant
plasmids were generated using the QuikChange II XL Site-Directed Mutagenesis
Kit (Agilent) and confirmed by Sanger sequencing. ZBTB7A wild type and mutants
were subcloned into pMSCV-IRES-YFP (pMIY), using the In-Fusion HD cloning
kit (Clontech) and EcoRI restriction sites. The pMSCV-IRES-GFP(pMIG)-
RUNX1/RUNX1T1 plasmid was provided by Christian Buske (Ulm).
DNA pull-down. HEK293T cells (DSMZ no.: ACC 635) were transfected with
pcDNA3.1 His-Xpress-ZBTB7A (wild type or mutant). After 24 h, protein was
extracted using lysis buffer (50 mM Tris HCl, pH 8.5, 150 mM NaCl, 1% Triton
X-100, cOmplete Protease Inhibitor Cocktail). For each reaction, 20 ml protein
lysate was incubated in binding buffer (PBS supplemented with 150 mM NaCl
resulting in a total salt concentration of nearly 300 mM, 0.1% NP40, 1 mM ETDA)
with 10 pM biotinylated double-stranded oligonucleotides that contain either the
ZBTB7A consensus binding motif (POK WT; 50-GGTTAAAAGACCCCTCCCCG
AATTCGGATC-30) or a mutant thereof (POK mut; 50-GGTTAAAATTTTTCTCC
CCGAATTCGGATC-30). After 1 h of incubation at 4 C, 10ml streptavidin agarose
beads (Sigma Aldrich) was added to each reaction and incubated for 30 min at 4 C.
Beads were washed three times with binding buffer and resupended in 10 ml
Laemmli buffer for subsequent western blot analysis. ZBTB7A protein was detected
using an antibody against the Xpress tag (1:5,000 dilution, clone R910-25; Life
Technologies) and secondary goat anti-mouse IgG-HRP (1:10,000 dilution, clone
sc-2060; Santa Cruz). The uncropped western blot scan underlying Fig. 2c is shown
in Supplementary Fig. 9.
Reporter gene assay. HEK293T cells (DSMZ no.: ACC 635) were co-transfected
with pcDNA3.1-His-ZBTB7A (wild type or mutant), pGL2-p19ARF-Luc (gift from
Takahiro Maeda, Boston) as well as pRL-CMV (Renilla luciferase; Promega) using
Lipofectamine 2000 (ThermoFischer). After 24 h, cells were lysed; Firefly and
Renilla luciferase activity was measured with the dual-luciferase reporter assay
system (Promega) according to the manufacturer’s instructions. Three independent
experiments were each performed in triplicates.
Western blot. HEK293T cells (DSMZ no.: ACC 635) were transfected using
Lipofectamine 2000 (ThermoFischer) with pcDNA3.1-His-ZBTB7A (wild type
or mutant). After 24 h, protein was either extracted by multiple freeze–thaw cycles
in lysis buffer (600 mM KCl, 20 mM Tris-Cl pH 7.8, 20% Glycerol, cOmplete
Protease Inhibitor Cocktail) or using the Qproteome Nuclear Protein Kit (Qiagen)
for the analysis of nuclear and cytoplasmic protein fractions. From archived patient
bone marrow samples, protein was isolated using the AllPrep DNA/RNA/Protein
Mini Kit (Qiagen) according to the manufacturer’s instructions. Following
SDS–polyacrylamide gel electrophoresis and protein transfer to polyvinylidene
difluoride membrane (Hybond PTM, Amersham Pharmacia biotech),
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immunoblots were blocked with 5% nonfat dried milk, probed with anti-human
Pokemon (ZBTB7A) purified antibody (1:5,000 dilution, clone: 13E9; eBioscience)
and secondary anti-Armenian hamster IgG-HRP (1:10,000 dilution, clone: sc-2443;
Santa Cruz). As loading control immunoblots were incubated with rabbit anti-actin
(1:5,000 dilution, clone: sc-1616- R; Santa Cruz) and secondary goat anti-rabbit
IgG-HRP (1:10,000 dilution, clone: sc-2030; Santa Cruz). For analysis of the
nuclear and cytoplasmic ZBTB7A protein fractions, we used mouse anti-Xpress
tag (1:5,000 dilution, clone R910-25, Life Technologies) and secondary goat
anti-mouse IgG-HRP (1:10,000 dilution, clone: sc-2060; Santa Cruz). Mouse
anti-GAPDH (1:10,000 dilution, clone: sc-32233; Santa Cruz) served as loading
control for the cytoplasmic protein fraction. Proteins were detected with enhanced
chemiluminescence (ECL, Amersham, GE Healthcare).
Immunofluorescence staining. U2OS human osteosarcoma cells (ATTC no.:
HTB-96) were grown on coverslips and transiently transfected with pcDNA3.1-
His-ZBTB7A wild type and mutant constructs using PoliFect (Qiagen) according to
the manufacturer’s guidelines. Cells were fixed 48 h post transfection using
PBS 2% formaldehyde (37% stock solution; Merck Schuchardt) for 10 min,
permeabilized with PBS 0.5% Triton X-100 (Carl Roth) for 10 min and blocked for
1 h with PBS 2% bovine serum albumin (Albumin Fraction V, AppliChem).
Cells were then incubated with polyclonal rabbit His-probe (H-15) antibody
(1:50 dilution; Santa Cruz) for 1 h. After extensive washing with PBS 0.1% Tween
20 (Carl Roth), secondary antibody incubation was performed for 1 h with goat
anti-rabbit IgG (Hþ L), F(ab0)2 fragment Alexa Fluor 594 conjugate (1:500
dilution; Cell Signaling Technology). Counterstaining was performed using
NucBlue Reagent and ActinGreen 488 ReadyProbes Reagent (Life Technologies;
2 drops per ml) at room temperature for 20 min. Coverslips were mounted using
fluorescence mounting medium (DAKO). Specimens were analysed using a
confocal fluorescence laser scanning system (TCS SP5 II; Leica). For image
acquisition and processing, the LAS AF Lite Software (Leica) was used.
Retroviral transduction. Retroviral transduction of Kasumi-1 cells (DSMZ no.:
ACC 220) was accomplished as outlined previously30. In brief, HEK293T cells were
co-transfected with pMSCV-IRES-YFP (pMIY) vectors containing either wild-type
or mutant (A175fs, R402C) ZBTB7A and packaging plasmids. After 48 h, the cell
culture supernatant was collected, sterile filtered and used for viral loading of
RetroNectin (Takara Clontech)-coated plates. A total of 3 105 Kasumi-1 cells
were transduced per well. The percentage of YFP-positive cells was assessed on a
FACSCalibur flow cytometer (BD Biosciences). Three independent experiments
were each performed in duplicates.
Colony-forming cell assay. For in vitro CFC assays, bone marrow cells were
collected from the femur and pelvic girdle of wild-type mice (C57BL/6X129/J).
Lineage-negative haematopoietic progenitors were isolated using magnetic
separation (MACS, murine lineage depletion kit, Miltenyi biotech). Retrovirally
transduced cells were sorted for GFP/YFP and were plated in 1% myeloid-condi-
tioned methylcellulose containing Iscove’s modified Dulbecco medium-based
Methocult (Methocult M3434; StemCell Technologies) at a concentration of
500 cells per ml. Single-cell suspensions of colonies were serially replated at the
same concentration until the exhaustion of cell growth. Three independent
experiments were each performed in duplicates.
Analysis of clinical and gene expression data. Clinical relevance of ZBTB7A
mutations or expression levels was evaluated using the Kaplan–Meier method and
the log-rank test. Fisher’s exact test was used to compare categorical variables,
while Wilcoxon Mann–Whitney U-test was applied for continuous variables. All
patients included in this analysis were treated intensively with curative intent
according to the AMLCG protocols. Gene expression profiling was performed on
215 adult patients with cytogenetically normal AML, using Affymetrix Human
Genome (HG) U133A/B (n¼ 155) and HG U133Plus2.0 microarrays (n¼ 60).
The RMA method was used for data normalization, and probe set summarization
utilized custom chip definition files based on the GeneAnnot database (version
2.2.0). Probe set GC19M004001_at was used to determine ZBTB7A expression
levels. High ZBTB7A expression was defined as the highest (4th) quartile of
expression values observed in CN-AML patients. Patients with ZBTB7A expression
levels in the 1st to 3rd quartile were classified as having low expression. The
patients analysed here represent a subset of the previously published data set
GSE37642. Validation of the results was done using data sets from the Haemato
Oncology Foundation for Adults in the Netherlands (HOVON) study group
(GSE14468 and GSE1159)16,17.
Data availability. Data referenced in this study are available in the Gene
Expression Omnibus database with the accession codes GSE37642, GSE14468 and
GSE1159. The next-generation sequencing data that support the findings of this
study are available on request from the corresponding author (P.A.G). The data are
not publicly available due to them containing information that could compromise
research participant privacy or consent. Explicit consent to deposit raw-sequencing
data was not obtained from the patients, many samples were collected 410 years
ago. Thus, the vast majority of patients cannot be asked to provide their consent for
deposit of their comprehensive genetic data.
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